{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:31:13Z","timestamp":1740126673942,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathol. Oncol. Res."],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s12253-017-0317-0","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T04:55:26Z","timestamp":1507870526000},"page":"149-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2018-8413","authenticated-orcid":false,"given":"Anik\u00f3","family":"Mar\u00e1z","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e1s","family":"Csejtei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judit","family":"Kocsis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikl\u00f3s","family":"Sz\u0171cs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zsuzsanna","family":"Kah\u00e1n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gy\u00f6rgy","family":"Bodoky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdolna","family":"Dank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"Mangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e1nos","family":"R\u00e9v\u00e9sz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lajos","family":"G\u00e9czi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,13]]},"reference":[{"key":"317_CR1","unstructured":"Afinitor EMEA Summary of Product Characteristics: \n                    http:\/\/www.ema.europa.eu\/docs\/hu_HU\/document_library\/EPAR_-_Product_Information\/human\/001038\/WC500022814.pdf"},{"key":"317_CR2","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1101\/gad.1212704","volume":"18","author":"N Hay","year":"2004","unstructured":"Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18:1926\u20131945","journal-title":"Genes Dev"},{"key":"317_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1056\/NEJMoa022171","volume":"349","author":"HJ Eisen","year":"2003","unstructured":"Eisen HJ, Tuzcu M, Dorent R et al (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant patients. N Engl J Med 349:847\u2013858","journal-title":"N Engl J Med"},{"key":"317_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449\u2013456","journal-title":"Lancet"},{"key":"317_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1009290","volume":"364","author":"JC Yao","year":"2011","unstructured":"Yao JC, Shah MH, Ito T et al (2011) Everolimus for Advanced Pancreatic Neuroendocrine Tumors. N Engl J Med 364:514\u2013523","journal-title":"N Engl J Med"},{"key":"317_CR6","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","volume":"387","author":"JC Yao","year":"2016","unstructured":"Yao JC, Fazio N, Singh S et al (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387:968\u2013977","journal-title":"Lancet"},{"key":"317_CR7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga J, Campone M, Piccart M et al (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366:520\u2013529","journal-title":"N Engl J Med"},{"key":"317_CR8","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256\u20134265","journal-title":"Cancer"},{"key":"317_CR9","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2011.11.027","volume":"48","author":"E Calvo","year":"2011","unstructured":"Calvo E, Escudier B, Motzer RJ et al (2011) Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48:333\u2013339","journal-title":"Eur J Cancer"},{"key":"317_CR10","unstructured":"NCCN Guideline. \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf"},{"key":"317_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/annonc\/mdu259","volume":"25","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Schmidinger M et al (2014) Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:49\u201356","journal-title":"Ann Oncol"},{"key":"317_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.eururo.2015.01.005","volume":"67","author":"B Ljungberg","year":"2015","unstructured":"Ljungberg B, Bensalah K, Canfield S et al (2015) EAU Guidelines on Renal Cell Carcinoma: 2014 Update. Eur Urol 67:913\u2013924","journal-title":"Eur Urol"},{"key":"317_CR13","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Escudier B, McDermott DF, el al (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373:1803\u20131813","DOI":"10.1056\/NEJMoa1510665"},{"key":"317_CR14","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","volume":"373","author":"TK Choueiri","year":"2015","unstructured":"Choueiri TK, Escudier B, Powles T et al (2015) Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373:1814\u20131823","journal-title":"N Engl J Med"},{"key":"317_CR15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17:917\u2013927","journal-title":"Lancet Oncol"},{"key":"317_CR16","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomized, phase 2, open-label, multicenter trial. Lancet Oncol 16:1473\u20131482","journal-title":"Lancet Oncol"},{"key":"317_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1093\/annonc\/mdw328","volume":"27","author":"B Escudier","year":"2016","unstructured":"Escudier B, Porta C, Schmidinger M et al (2016) Renal Cell Carcinoma: ESMO Clinical Practice Guidelines. Ann Oncol 27:58\u201368","journal-title":"Ann Oncol"},{"key":"317_CR18","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205\u2013214","journal-title":"J Natl Cancer Inst"},{"key":"317_CR19","unstructured":"Common Terminology Criteria for Adverse Events, version 3.0 issued by National Cancer Institute EORTC, 09. 08 (2006) \n                    http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf"},{"key":"317_CR20","unstructured":"ECOG performance status. \n                    http:\/\/ecog.dfci.harvard.edu\/general\/perf_stat.html"},{"key":"317_CR21","first-page":"543","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Flaherty K (2008) Clinical effect and future considerations for molecularly-targeted therapy in renal cancer. Uro Oncol Semin Orig Investig 26:543\u2013549","journal-title":"Uro Oncol Semin Orig Investig"},{"key":"317_CR22","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ejca.2011.06.054","volume":"48","author":"V Gr\u00fcnwald","year":"2012","unstructured":"Gr\u00fcnwald V, Karakiewicz PI, Bavbek SE et al (2012) An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur J Cancer 48:324\u2013332","journal-title":"Eur J Cancer"},{"key":"317_CR23","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ctrv.2012.06.010","volume":"39","author":"E Calvo","year":"2013","unstructured":"Calvo E, Ravaud A, Bellmunt J (2013) What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? Cancer Treat. Rev. 39:366\u2013374","journal-title":"Cancer Treat. Rev."},{"key":"317_CR24","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1186\/s12885-015-1309-7","volume":"15","author":"L Bergmann","year":"2015","unstructured":"Bergmann L, Kube U, Doehn C et al (2015) Everolimus in metastatic renal cell carcinoma after failure of initial anti\u2013VEGF therapy: final results of a noninterventional study. BMC Cancer 15:303","journal-title":"BMC Cancer"},{"key":"317_CR25","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","volume":"22","author":"RJ Motzer","year":"2004","unstructured":"Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454\u2013463","journal-title":"J Clin Oncol"}],"container-title":["Pathology & Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12253-017-0317-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0317-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12253-017-0317-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T01:29:01Z","timestamp":1567733341000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12253-017-0317-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,13]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["317"],"URL":"https:\/\/doi.org\/10.1007\/s12253-017-0317-0","relation":{},"ISSN":["1219-4956","1532-2807"],"issn-type":[{"type":"print","value":"1219-4956"},{"type":"electronic","value":"1532-2807"}],"subject":[],"published":{"date-parts":[[2017,10,13]]},"assertion":[{"value":"10 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Anik\u00f3 Mar\u00e1z has received honoraria from Bayer, Bristol-Myers Squibb, and has served on advisory boards for Novartis.Andr\u00e1s Csejtei has served on advisory boards for Novartis and Pfizer.Judit Kocsis has received honoraria from Bayer and served as a member of advisory board: Novartis, Bristol-Myers Squibb and Pfizer.Mikl\u00f3s Sz\u0171cs has received honoraria from Bayer, Novartis, Bristol-Myers Squibb and has served on advisory boards for Novartis and Pfizer.Zsuzsanna Kah\u00e1n has no actual or potential conflicts of interest to report.Gy\u00f6rgy Bodoky has received honoraria from Bayer, Bristol-Myers Squibb and Pfizer and has served on advisory boards for Novartis and Pfizer.Magdolna Dank has received honoraria from Bayer, Novartis and Pfizer and has served on advisory boards for Novartis and Pfizer.L\u00e1szl\u00f3 Mangel has received honoraria from Pfizer and has served on advisory boards for Novartis and Pfizer.J\u00e1nos R\u00e9v\u00e9sz has served on advisory boards for Novartis and Pfizer.Zolt\u00e1n Varga has no actual or potential conflicts of interest to report.Lajos G\u00e9czi has received honoraria from Bayer, Novartis, Bristol-Myers Squibb and Pfizer and has served on advisory boards for Bristol-Myers Squibb, Novartis and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study no formal consent is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"This was a non-sponsored study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Support"}}]}}